돼지 백신 시장 예측(2026-2032년)

The Swine Vaccines Market is projected to grow by USD 3.01 billion at a CAGR of 6.30% by 2032.

Swine vaccines are central to modern pork production, supporting animal health, food security, antimicrobial stewardship, and continuity of international livestock trade. The sector is shaped by persistent disease pressure from economically important pathogens such as porcine reproductive and respiratory syndrome virus, porcine circovirus type 2, Mycoplasma hyopneumoniae, swine influenza virus, classical swine fever virus, and African swine fever virus. While some diseases are routinely managed through established immunization programs, others continue to drive urgent research into safer, more effective, and more scalable vaccine technologies.

Demand for swine vaccination is increasingly linked to herd-level prevention rather than reactive disease control. Producers, veterinarians, integrators, and public animal health agencies are prioritizing vaccination protocols that reduce mortality, improve reproductive performance, lower clinical disease burden, and limit secondary bacterial infections that can otherwise increase antibiotic use. Regulatory scrutiny, biosecurity standards, disease surveillance, and consumer expectations for responsibly produced pork are reinforcing the role of vaccination as a core pillar of swine health management.

The swine vaccines landscape spans live attenuated, inactivated, subunit, recombinant, vector-based, and autogenous vaccines, with innovation concentrated on broader protection, DIVA-compatible diagnostics, improved adjuvants, needle-free administration, thermostability, and rapid strain matching. As pig production systems become more intensive and globally connected, vaccine strategy is moving toward integrated disease prevention supported by diagnostics, farm data, and region-specific epidemiology.

Transformative Shifts in the Swine Vaccines Landscape

The swine vaccines landscape is undergoing transformative shifts driven by disease complexity, evolving production models, and tighter alignment between animal health and public health objectives. African swine fever has highlighted the vulnerability of pig supply chains to transboundary disease, even in regions with advanced veterinary infrastructure. Because no broadly commercialized, globally deployed African swine fever vaccine has historically been available, prevention has depended heavily on biosecurity, surveillance, movement control, and culling policies, while research has accelerated into live attenuated, gene-deleted, vectored, and subunit vaccine candidates.

Porcine reproductive and respiratory syndrome remains one of the most challenging endemic diseases for pork producers due to viral diversity, immune evasion, and herd-to-herd transmission dynamics. This has intensified interest in more precise vaccine matching, improved monitoring of circulating strains, and combined vaccination-biosecurity protocols. At the same time, long-established vaccination against PCV2 has demonstrated the value of herd-wide immunization in reducing clinical disease and improving production consistency.

The industry is also shifting from single-product decision-making toward comprehensive health programs. Vaccination choices are increasingly evaluated alongside gilt acclimatization, pig flow, all-in/all-out management, sanitation, ventilation, colostrum management, and diagnostic testing. This systems-based approach is particularly important in high-density swine regions, where pathogen circulation and co-infections can reduce vaccine performance if underlying management gaps remain unresolved.

Another major shift is the rise of precision livestock health. Digital recordkeeping, automated monitoring, and laboratory networks are enabling faster detection of disease deviations and more evidence-based vaccine scheduling. Needle-free delivery, combination vaccines, and improved administration protocols are gaining relevance as farms seek to reduce labor burden, enhance animal welfare, and improve compliance across large populations.

Cumulative Impact of Artificial Intelligence on Swine Vaccines

Artificial intelligence is beginning to reshape swine vaccine development, disease surveillance, and herd health decision-making. In vaccine research, AI-supported bioinformatics can help identify conserved antigens, evaluate immune-relevant protein structures, compare viral and bacterial genomes, and prioritize candidates for laboratory validation. This is particularly relevant for pathogens with high genetic variability, including PRRSV and swine influenza, where strain diversity complicates durable protection.

AI can also strengthen real-time disease intelligence by integrating veterinary diagnostic results, farm production records, mortality trends, feed intake, climate data, movement data, and regional outbreak notifications. When applied responsibly, these tools can help veterinarians detect abnormal patterns earlier, refine vaccination timing, and identify farms or production stages at elevated disease risk. Predictive analytics may support better allocation of diagnostic sampling and faster response to emerging variants or transboundary disease threats.

In manufacturing and quality systems, AI-enabled process analytics can support consistency by monitoring bioreactor performance, antigen yield, sterility parameters, and batch deviations. For autogenous and regionally tailored vaccines, data-driven workflows may shorten the time between pathogen identification and vaccine formulation decisions, while still requiring rigorous regulatory and safety oversight.

The cumulative impact of AI is therefore not the replacement of veterinary expertise, but the amplification of evidence-based prevention. Its value depends on data quality, interoperability, cybersecurity, transparent model validation, and alignment with animal welfare and regulatory requirements. The most meaningful adoption will occur where AI tools are embedded into veterinarian-led herd health programs and validated against field outcomes.

Key Regional Insights for Swine Vaccines

Asia-Pacific represents one of the most strategically important regions for swine vaccines because it includes several of the world's largest pork-producing and pork-consuming countries. China remains central to regional disease dynamics due to the scale of its pig population and the lasting impact of African swine fever outbreaks on production systems, biosecurity investment, and vaccine research priorities. Southeast Asian countries continue to face endemic and emerging disease pressure, including classical swine fever, PRRS, PCV2-associated disease, and African swine fever incursions, making vaccination programs closely linked with surveillance, smallholder outreach, and farm modernization. Japan, South Korea, and Australia maintain advanced veterinary regulatory systems and high biosecurity expectations, with Australia's disease-free status for several major swine pathogens shaping a prevention-first approach.

Europe has one of the most regulated animal health environments, with the European Union's Animal Health Law, surveillance systems, and farm biosecurity standards shaping vaccine deployment and disease response. African swine fever in wild boar and domestic pigs has had a major influence on regional control strategies, particularly in Eastern and Central Europe. Western European production systems emphasize vaccination as part of integrated health management, antimicrobial reduction targets, and high welfare expectations, while continued monitoring of PRRS, PCV2, Mycoplasma hyopneumoniae, swine influenza, and enteric diseases supports farm-specific vaccine protocols.

North America is characterized by highly integrated pork production, strong veterinary diagnostic capacity, and widespread adoption of vaccines against PRRS, PCV2, Mycoplasma hyopneumoniae, swine influenza, and other production-limiting pathogens. The United States and Canada emphasize coordinated surveillance, herd health planning, and rapid diagnostic confirmation, while Mexico's swine sector combines commercial integration with regional disease control priorities. Antimicrobial stewardship and supply chain continuity are key drivers of vaccine program optimization across the region.

Latin America has a diverse swine health environment, with Brazil and Mexico playing prominent roles in commercial pork production. Brazil's export-oriented pork sector places strong emphasis on disease status, veterinary controls, and preventive health programs, while regional differences in farm scale and infrastructure influence vaccination coverage across Latin America. Classical swine fever control remains relevant in parts of the region, and African swine fever preparedness has become a policy priority following re-emergence in the Caribbean.

Africa presents a complex swine vaccine landscape shaped by smallholder production, limited veterinary access in some areas, and recurring African swine fever outbreaks. The disease is endemic in parts of sub-Saharan Africa, where interactions among domestic pigs, wild suids, ticks, and informal pig movement can complicate control. Vaccination opportunities are closely tied to diagnostic access, extension services, cold chain reliability, and locally appropriate disease prevention strategies.

The Middle East has a comparatively smaller commercial swine footprint due to dietary, religious, and market factors, but animal health infrastructure remains important for biosecurity, border inspection, and disease reporting. Swine vaccine relevance is concentrated in specific production, research, and expatriate consumption contexts, while regional veterinary systems often prioritize transboundary disease preparedness across livestock species.

Key Group Insights for Swine Vaccines

NATO members are not a veterinary market bloc, but many members overlap with major swine-producing countries in North America and Europe. For these countries, animal health security intersects with national resilience, food system continuity, biosecurity, and protection against accidental or deliberate disruption of agricultural supply chains. Swine vaccine readiness is therefore part of a broader One Health and agricultural security context, particularly for preparedness against transboundary diseases such as African swine fever and classical swine fever.

G7 countries generally have mature veterinary regulatory systems, strong diagnostic capacity, and advanced research ecosystems, supporting high standards for vaccine safety, efficacy evaluation, and post-market monitoring. Within the G7, swine vaccination is closely connected to food supply resilience, responsible antibiotic use, animal welfare expectations, and preparedness for emerging or re-emerging livestock diseases.

BRICS countries collectively represent substantial influence over global swine health because China, Brazil, Russia, and India each have distinct production systems, disease challenges, and veterinary policy priorities. China's African swine fever experience has accelerated biosecurity and vaccine research, Brazil's export orientation strengthens disease prevention standards, Russia's regional disease control needs are shaped by large geography and ASF exposure, and India's growing livestock health agenda includes improving veterinary access and disease monitoring in diverse production settings.

The European Union plays an influential role in swine vaccine governance through harmonized animal health regulations, pharmacovigilance requirements, disease notification systems, and antimicrobial stewardship policies. EU member states use vaccination within broader prevention frameworks that include biosecurity, traceability, movement controls, and surveillance. African swine fever management has reinforced the need for coordinated regional response, especially where wild boar reservoirs sustain disease pressure.

ASEAN's swine vaccine priorities are shaped by dense pig populations in several member countries, mixed commercial and smallholder systems, and ongoing exposure to African swine fever, PRRS, classical swine fever, and other endemic diseases. The region's vaccination strategies increasingly depend on coordinated surveillance, farmer education, vaccine accessibility, and cross-border disease notification, particularly where informal animal movement can accelerate pathogen spread.

The GCC has limited swine production because of cultural and religious factors, yet it remains relevant to veterinary public policy through import controls, quarantine systems, laboratory readiness, and regional biosecurity planning. Swine vaccine demand is therefore highly specialized, but animal disease preparedness across the GCC benefits from investments in diagnostic infrastructure and transboundary disease monitoring.

Key Country Insights for Swine Vaccines

China remains one of the most consequential countries for swine vaccines due to the scale of its pig industry and the profound restructuring that followed African swine fever outbreaks. Large-scale farms have expanded biosecurity and veterinary protocols, while disease control continues to focus on ASF preparedness, PRRS, PCV2, classical swine fever, and other endemic pathogens. The United States has a large, highly integrated pork sector where vaccination programs are central to controlling PRRS, PCV2, Mycoplasma hyopneumoniae, swine influenza, erysipelas, and other production diseases. Strong diagnostic networks, veterinarian-led health planning, and biosecurity protocols guide vaccine selection and timing. Japan has high biosecurity standards and a sophisticated veterinary framework, with vaccination decisions shaped by disease status, regulatory controls, and food safety expectations. India's swine sector is smaller than its broader livestock economy but important in specific regions, particularly in the northeast, where vaccination, veterinary access, and disease awareness are critical for smallholder resilience.

Germany, France, Italy, and Spain are major European pork producers where vaccination is embedded in integrated health management, antimicrobial reduction efforts, and compliance with European regulatory standards. Germany emphasizes biosecurity, welfare, and surveillance, while France combines structured veterinary oversight with disease prevention across diverse production models. Spain's intensive pork production system makes disease prevention, PRRS control, and coordinated veterinary oversight especially important. Italy's diversified production, including specialty pork supply chains, places value on herd stability, traceability, and disease prevention. The United Kingdom maintains rigorous disease surveillance and biosecurity protocols, with swine vaccines used in targeted health programs that reflect farm-specific disease history and veterinary guidance.

Australia maintains strict biosecurity and border controls to protect its animal health status, using vaccination where appropriate while prioritizing exclusion of major exotic swine diseases. South Korea combines modern commercial production with strong government-led disease control measures, shaped by experiences with African swine fever and other livestock disease threats. Canada emphasizes herd health planning, traceability, and disease prevention, with export-oriented production reinforcing strict veterinary standards. Russia faces significant regional swine disease challenges, including African swine fever exposure, making surveillance, biosecurity, and vaccine research priorities for domestic pork resilience.

Brazil is a leading pork producer with strong export ambitions, so preventive vaccination, disease monitoring, and maintenance of recognized animal health status are strategically important. The country's commercial sector uses structured herd health programs, while regional differences require adaptable veterinary outreach. Mexico combines major commercial pork operations with regionally varied production systems, making vaccine access, disease surveillance, and biosecurity important across different farm scales.

Actionable Recommendations for Swine Vaccine Leaders

Industry leaders should prioritize integrated swine health programs that combine vaccination, diagnostics, biosecurity, nutrition, welfare, and farm management rather than relying on vaccines as standalone interventions. Vaccine protocols should be built from farm-specific disease history, laboratory confirmation, pathogen sequencing where relevant, production stage risk, maternal antibody status, and veterinarian-supervised outcome monitoring.

Manufacturers and research teams should invest in vaccine platforms that address antigenic diversity, rapid strain adaptation, DIVA compatibility, improved safety profiles, and practical administration in large herds. African swine fever, PRRS, and swine influenza require continued scientific focus because of their economic consequences, genetic variability, and implications for trade and food security.

Producers should strengthen cold chain handling, staff training, accurate dosing, booster compliance, and post-vaccination monitoring to protect vaccine effectiveness. Digital herd records should be used to connect vaccination events with mortality, morbidity, reproductive performance, medication use, and diagnostic results. This creates a feedback loop for evidence-based protocol refinement.

Policy stakeholders should support transparent disease reporting, regional laboratory capacity, responsible vaccine authorization, and farmer education programs, especially in areas with smallholder production and limited veterinary access. Cross-border collaboration is essential for transboundary diseases, as pathogen movement rarely follows administrative boundaries.

Across the value chain, leaders should align swine vaccination strategies with antimicrobial stewardship and One Health objectives. Demonstrating reductions in clinical disease, secondary infections, and antibiotic dependence can strengthen stakeholder confidence and support sustainable pork production.

Research Methodology for Swine Vaccines Analysis

This executive summary is developed using a structured secondary research approach focused on verified animal health, veterinary epidemiology, and regulatory information. Core inputs include publicly available materials from national veterinary authorities, intergovernmental animal health organizations, peer-reviewed scientific literature, disease notification systems, livestock health guidelines, and recognized veterinary public health sources.

The methodology emphasizes triangulation across multiple credible references to validate disease relevance, regional patterns, vaccine use context, and technology trends. Insights are assessed for consistency with established swine health knowledge, including pathogen epidemiology, production system characteristics, biosecurity practices, and regulatory frameworks. Particular attention is given to avoiding unsupported claims, speculative commercial projections, and unverified performance assertions.

Qualitative analysis is used to interpret how disease burden, farming structure, veterinary infrastructure, regulatory policy, and biosecurity maturity influence swine vaccine adoption. Regional, group, and country-level insights are synthesized into narrative form to support search visibility while maintaining evidence-based accuracy. The analysis excludes market sizing, market share, and forecasting, focusing instead on strategic, operational, scientific, and policy-relevant developments.

Conclusion: Advancing Resilient Swine Health Through Vaccination

Swine vaccines are becoming increasingly important as pork producers and animal health authorities confront endemic respiratory, reproductive, enteric, and systemic diseases alongside high-impact transboundary threats. The strongest vaccination outcomes occur when immunization is integrated with diagnostics, biosecurity, surveillance, farm management, and veterinarian-led decision-making.

The landscape is shifting toward precision prevention, supported by improved vaccine platforms, farm data, sequencing, digital monitoring, and AI-assisted analytics. However, successful implementation will depend on field validation, regulatory oversight, cold chain reliability, producer training, and regionally appropriate disease control strategies.

Across Asia-Pacific, Europe, North America, Latin America, Africa, and the Middle East, swine vaccine priorities differ by production scale, disease status, veterinary infrastructure, and policy environment. Yet the strategic direction is consistent: healthier herds, reduced disease losses, improved antimicrobial stewardship, and stronger resilience of pork supply chains. Stakeholders that align vaccine innovation with practical farm execution and transparent disease intelligence will be best positioned to advance sustainable swine health.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Swine Vaccines Market, by Vaccine Type

• 7.1. Introduction
• 7.2. Inactivated Vaccine
  • 7.2.1. Split Virus
  • 7.2.2. Subcellular
  • 7.2.3. Whole Virus
• 7.3. Live Attenuated Vaccine
  • 7.3.1. Heterologous
  • 7.3.2. Homologous
• 7.4. MRNA
  • 7.4.1. Non Amplifying MRNA
  • 7.4.2. Self Amplifying MRNA
• 7.5. Subunit Vaccine
  • 7.5.1. Polysaccharide Subunit
  • 7.5.2. Protein Subunit

8. Swine Vaccines Market, by Route Of Administration

• 8.1. Introduction
• 8.2. Injection
• 8.3. Nasal
• 8.4. Oral

9. Swine Vaccines Market, by Packaging Type

• 9.1. Introduction
• 9.2. Multi Dose Bottle
• 9.3. Pre Filled Syringe
• 9.4. Vial

10. Swine Vaccines Market, by End User

• 10.1. Introduction
• 10.2. Commercial Farms
• 10.3. Research Institutes
• 10.4. Veterinary Clinics
• 10.5. Veterinary Hospitals

11. Swine Vaccines Market, by Disease Type

• 11.1. Introduction
• 11.2. Classical Swine Fever
• 11.3. Erysipelas
• 11.4. Mycoplasma Pneumonia
• 11.5. Porcine Circovirus
• 11.6. Porcine Reproductive And Respiratory Syndrome
• 11.7. Swine Influenza

12. Swine Vaccines Market, by Technology

• 12.1. Introduction
• 12.2. Conventional
  • 12.2.1. Attenuated Live
  • 12.2.2. Killed Whole
• 12.3. DNA
• 12.4. Recombinant
  • 12.4.1. Bacteria Expressed
  • 12.4.2. Insect Cell Expressed
  • 12.4.3. Yeast Expressed
• 12.5. RNA
• 12.6. VLP

13. Swine Vaccines Market, by Region

• 13.1. Asia-Pacific
• 13.2. Europe
• 13.3. North America
• 13.4. Latin America
• 13.5. Africa
• 13.6. Middle East

14. Swine Vaccines Market, by Group

• 14.1. NATO
• 14.2. G7
• 14.3. BRICS
• 14.4. European Union
• 14.5. ASEAN
• 14.6. GCC

15. Swine Vaccines Market, by Country

• 15.1. China
• 15.2. United States
• 15.3. Japan
• 15.4. India
• 15.5. Germany
• 15.6. United Kingdom
• 15.7. Australia
• 15.8. France
• 15.9. South Korea
• 15.10. Italy
• 15.11. Canada
• 15.12. Russia
• 15.13. Brazil
• 15.14. Mexico
• 15.15. Spain

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. FPNV Positioning Matrix, 2025
• 16.3. Market Concentration Analysis, 2025
  • 16.3.1. Concentration Ratio (CR)
  • 16.3.2. Herfindahl Hirschman Index (HHI)
• 16.4. Recent Developments & Impact Analysis, 2025
• 16.5. Product Portfolio Analysis, 2025
• 16.6. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Aptimmune Biologics, Inc.
• 17.2. Arko Laboratories
• 17.3. AVAC Vietnam Joint Stock Company
• 17.4. Bayer AG
• 17.5. Bimeda Holdings PLC
• 17.6. Biogenesis Bago S.A.
• 17.7. Boehringer Ingelheim International GmbH
• 17.8. Ceva Sante Animale
• 17.9. Eli Lilly and Company
• 17.10. Endovac Animal Health
• 17.11. FATRO S.p.A.
• 17.12. Formosa Biomedical Inc.
• 17.13. Genvax Technologies, Inc.
• 17.14. HIPRA, S.A.
• 17.15. Indian Immunologicals Ltd.
• 17.16. KM Biologics Co., Ltd.
• 17.17. Kyoto Biken Laboratories, Inc.
• 17.18. Malaysian Vaccines & Pharmaceuticals Sdn Bhd.
• 17.19. Medgene Labs
• 17.20. Merck & Co., Inc.
• 17.21. Nisseiken Co., Ltd.
• 17.22. PBS Animal Health
• 17.23. Phibro Animal Health Corporation
• 17.24. Virbac SA
• 17.25. Yenher Agro-Products Sdn. Bhd.
• 17.26. Zoetis Inc.